• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, January 1, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Managing architectural distortion on mammography based on MR enhancement

Bioengineer by Bioengineer
May 5, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results to be exhibited at 2019 ARRS Annual Meeting

Leesburg, VA, May 5, 2019–High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US) correlate or magnetic resonance imaging (MRI) enhancement suggests follow-up rather than biopsy may be safely performed, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

Management of MG-detected AD varies among practices when tomosynthesis-guided biopsy is not available. The study was conducted to evaluate outcomes of architectural distortion on mammography (MG) with or without a magnetic resonance (MR) correlate.

Unexplained AD on MG cases with subsequent MR were retrospectively reviewed by MG type, biopsy type and cancer results, cancer type, tumor grade, and receptor status. Among the study group of 57 patients, the NPV of MG AD without MR correlate or enhancement was 97.2%. Forty-four of 57 had MG AD without US correlate. Of 12 patients without US but with MR correlate, cancers (25%) were masses on MR, majority of benign findings (58.3%) were nonmass enhancement (NME), and RS/CSL (41.7%) was mass or NME. No MG AD without US or MR correlate was found to be cancer. The NPV of MG AD without US or MR correlate or enhancement was 100%.

The results indicate that follow-up rather than biopsy may be safely performed in cases of MG AD without US and MRI correlate or enhancement, reducing the need for intervention and lowering healthcare costs.

“With 3D tomosynthesis widely incorporated in many practices, MG AD without US or MRI correlate poses a management dilemma to radiologists,” author of the study Vandana Dialani, MD said. “This study is especially important for institutions which do not have tomo-guided biopsy capabilities and may revert to contrast imaging as a next step in managing MG AD. Our study shows that the NPV of MG AD without US correlate or MR enhancement was 100% and follow-up rather than biopsy may be considered.”

###

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

Media Contact
Alycia Tessean
[email protected]
https://arrs.org/ARRSLIVE/Pressroom/PressReleases/mammography_architectural_distortion_mr_enhancement.aspx

Tags: Breast CancercancerHealth Care Systems/ServicesHealth ProfessionalsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Derazantinib Boosts Gemcitabine by Blocking MUC5AC

December 30, 2025

FOCUS Study Reveals Insights on Melphalan for Uveal Melanoma

December 29, 2025

Black Grape Anthocyanins Boost 5-FU Cancer Therapy

December 29, 2025

Girdin Silencing Boosts Mebendazole’s Ovarian Cancer Fight

December 29, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    PTSD, Depression, Anxiety in Childhood Cancer Survivors, Parents

    108 shares
    Share 43 Tweet 27
  • NSF funds machine-learning research at UNO and UNL to study energy requirements of walking in older adults

    71 shares
    Share 28 Tweet 18
  • Exploring Audiology Accessibility in Johannesburg, South Africa

    52 shares
    Share 21 Tweet 13
  • SARS-CoV-2 Subvariants Affect Outcomes in Elderly Hip Fractures

    44 shares
    Share 18 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Paintable Soft Photonics with Multi-Stable Light Activation

Model-Free Optical Processors Learn via Proximal Policy Optimization

Preterm Birth’s Impact on Childhood Psychomotor Skills

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 71 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.